The stock of Abeona Therapeutics Inc (ABEO) has seen a -49.59% decrease in the past week, with a -48.83% drop in the past month, and a -23.51% decrease in the past quarter. The volatility ratio for the week is 11.80%, and the volatility levels for the past 30 days are at 7.91% for ABEO. The simple moving average for the last 20 days is -44.98% for ABEO stock, with a simple moving average of -26.39% for the last 200 days.
Is It Worth Investing in Abeona Therapeutics Inc (NASDAQ: ABEO) Right Now?
Additionally, the 36-month beta value for ABEO is 1.59. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABEO is 25.91M and currently, short sellers hold a 7.96% ratio of that float. The average trading volume of ABEO on April 29, 2024 was 519.84K shares.
ABEO) stock’s latest price update
The stock price of Abeona Therapeutics Inc (NASDAQ: ABEO) has surged by 13.80 when compared to previous closing price of 3.26, but the company has seen a -49.59% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-23 that Abeona Therapeutics Inc. stock dropped by over half after receiving a Complete Response Letter from the FDA regarding its Biologics License Application for pz-cel. The FDA identified manufacturing issues that need to be resolved, delaying the potential approval of pz-cel. However, no issues were raised regarding efficacy and safety, nor are more trials required. Despite the setback, Abeona Therapeutics may present a buying opportunity as it bottoms out, with estimated peak revenue of over $500 million in the U.S. assuming approval.
Analysts’ Opinion of ABEO
Many brokerage firms have already submitted their reports for ABEO stocks, with Cantor Fitzgerald repeating the rating for ABEO by listing it as a “Overweight.” The predicted price for ABEO in the upcoming period, according to Cantor Fitzgerald is $4 based on the research report published on November 11, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $5. The rating they have provided for ABEO stocks is “Buy” according to the report published on September 18th, 2020.
SVB Leerink gave a rating of “Outperform” to ABEO, setting the target price at $6 in the report published on February 10th of the previous year.
ABEO Trading at -48.58% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.82% of loss for the given period.
Volatility was left at 7.91%, however, over the last 30 days, the volatility rate increased by 11.80%, as shares sank -52.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.45% lower at present.
During the last 5 trading sessions, ABEO fell by -50.14%, which changed the moving average for the period of 200-days by -8.02% in comparison to the 20-day moving average, which settled at $6.54. In addition, Abeona Therapeutics Inc saw -25.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABEO starting from Charles Faith L., who purchase 7,550 shares at the price of $3.28 back on Apr 26 ’24. After this action, Charles Faith L. now owns 78,323 shares of Abeona Therapeutics Inc, valued at $24,764 using the latest closing price.
Seshadri Vishwas, the Chief Executive Officer of Abeona Therapeutics Inc, purchase 10,000 shares at $3.20 during a trade that took place back on Apr 25 ’24, which means that Seshadri Vishwas is holding 538,260 shares at $32,000 based on the most recent closing price.
Stock Fundamentals for ABEO
Current profitability levels for the company are sitting at:
- -13.77 for the present operating margin
- 0.09 for the gross margin
The net margin for Abeona Therapeutics Inc stands at -15.48. The total capital return value is set at -0.95. Equity return is now at value -260.60, with -84.53 for asset returns.
Based on Abeona Therapeutics Inc (ABEO), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -6.85. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -115.31.
Currently, EBITDA for the company is -45.0 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 26.23. The receivables turnover for the company is 1.43for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
In conclusion, Abeona Therapeutics Inc (ABEO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
